Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$237.00 USD

237.00
671,048

+2.53 (1.08%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $236.96 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for United Therapeutics Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 2,994 2,839 1,931 1,835 1,486
Receivables 279 220 199 157 151
Notes Receivable 0 0 0 0 0
Inventories 112 102 94 87 93
Other Current Assets 166 219 100 88 134
Total Current Assets 3,551 3,380 2,324 2,167 1,865
Net Property & Equipment 1,045 862 781 732 739
Investments & Advances 1,910 1,316 1,650 1,150 768
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 395 328 262 239 230
Intangibles 114 45 45 158 158
Deposits & Other Assets 152 114 108 170 155
Total Assets 7,167 6,045 5,169 4,615 3,913
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 298 230 175 187 148
Current Portion Long-Term Debt 400 0 0 0 250
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 106 113 131 136 65
Total Current Liabilities 804 343 305 323 463
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 300 800 800 800 600
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 78 105 105 97 70
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,182 1,248 1,210 1,220 1,133
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 2,549 2,388 2,245 2,149 2,048
Retained Earnings 6,027 5,042 4,315 3,839 3,325
Other Equity -13 -56 -23 -14 -14
Treasury Stock 2,579 2,579 2,579 2,579 2,579
Total Shareholder's Equity 5,985 4,797 3,959 3,395 2,780
Total Liabilities & Shareholder's Equity 7,167 6,045 5,169 4,615 3,913
Total Common Equity 5,985 4,797 3,959 3,395 2,780
Shares Outstanding 46.90 45.50 45.00 44.40 43.80
Book Value Per Share 127.61 105.42 87.98 76.47 63.48

Fiscal Year End for United Therapeutics Corporation falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 2,994 2,876 2,679 2,863
Receivables NA 279 259 273 135
Notes Receivable NA 0 0 0 0
Inventories NA 112 104 103 103
Other Current Assets NA 166 221 158 93
Total Current Assets NA 3,551 3,459 3,213 3,193
Net Property & Equipment NA 1,045 992 939 897
Investments & Advances NA 1,910 2,061 2,024 1,766
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 395 326 326 322
Intangibles NA 114 44 45 45
Deposits & Other Assets NA 152 142 135 125
Total Assets NA 7,167 7,024 6,681 6,346
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 298 333 292 240
Current Portion Long-Term Debt NA 400 300 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 106 111 78 85
Total Current Liabilities NA 804 744 370 325
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 300 500 800 800
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 67 100 98
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,182 1,312 1,270 1,223
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 2,549 2,524 2,498 2,457
Retained Earnings NA 6,027 5,810 5,542 5,283
Other Equity NA -13 -44 -51 -39
Treasury Stock NA 2,579 2,579 2,579 2,579
Total Shareholder's Equity NA 5,985 5,712 5,411 5,123
Total Liabilities & Shareholder's Equity NA 7,167 7,024 6,681 6,346
Total Common Equity 0 5,985 5,712 5,411 5,123
Shares Outstanding 47.00 46.90 46.90 46.90 46.80
Book Value Per Share 0.00 127.61 121.79 115.37 109.47